<DOC>
	<DOC>NCT00407589</DOC>
	<brief_summary>This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exposure to BOL-303224-A following single and multiple topical administration of BOL-303224-A in participants with suspected bacterial conjunctivitis.</brief_summary>
	<brief_title>Systemic Pharmacokinetics of BOL-303224-A</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Bacterial</mesh_term>
	<mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<criteria>must be at least 18 years of age, any race must have a clinical diagnosis of acute bacterial conjunctivitis and exhibit purulent conjunctival discharge and redness in both eyes women of childbearing potential must utilize reliable contraceptive methods and have a negative pregnancy test Pregnant or nursing women known hypersensitivity to fluoroquinolones or to any of the ingredients in the study medication use of any antibiotic within 72 hours of enrollment participation in an ophthalmic drug or devise research study within 30 days prior to entry in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>